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Abstract
Background: Gastroenteropancreatic neuroendocrine tumours (GEP-NET) are often slow-growing and patients may
live for years with metastasised disease. Hence, along with increasing overall and progression-free survival, treatments
aim at preserving patients’ well-being and health-related quality of life (HRQoL). However, studies on systematic HRQoL
assessment in patients with GEP-NET are scarce. Therefore, the purpose of the current review is to systematically
evaluate the methodological quality of the identified studies.
Methods: A targeted database search was performed in PubMed, EMBASE, and CENTRAL. Data extraction was
conducted by two independent researchers according to predefined criteria. For study evaluation, the Minimum
Standard Checklist for Evaluating HRQoL Outcomes in Cancer Clinical Trials and the CONSORT Patient-Reported
Outcome extension were adapted.
Results: The database search yielded 48 eligible studies. We found the awareness for the need of HRQoL
measurement to be growing and application of cancer-specific instruments gaining acceptance. Overall, studies were
too heterogeneous in terms of patient characteristics and treatment interventions to draw clear conclusions for clinical
practice. More importantly, a range of methodological shortcomings has been identified which were mainly related to
the assessment and statistical analysis, as well as the reporting and interpretation of HRQoL data.
Conclusion: Despite an increasing interest in HRQoL in GEP-NET patients, there is still a lack of knowledge on this
issue. A transfer of HRQoL results into clinical practice is hindered not only by the scarceness of studies, but also by the
often limited quality of HRQoL processing and reporting.
Keywords: Health-related quality of life, Gastroenteropancreatic neuroendocrine tumours, Patient-reported outcomes,
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Background
With an incidence of 5.25 per 100,000 [1] gastroenter-
opancreatic neuroendocrine tumours (GEP-NET) are
a relatively rare disease. They are usually slow-
growing and often do not produce clear symptoms
until they are metastasised. Currently, surgical tumour
resection is the only curative treatment, and usually
only in patients with localised disease [1–4]. The pri-
mary aims of available therapeutic options are to pro-
vide symptom relief, control tumour growth, improve
long-term survival, and, not least, preserve psycho-
social well-being and health-related quality of life
(HRQoL) [2, 4].
The past two decades have shown that the patient’s
subjective perspective on his/her own health, quality of
life, and treatment-related aspects plays an essential role
in treatment evaluation. Traditional physician proxy
ratings on morbidity correlate only poorly with several
self-reported functional capacity and well-being domains
[5] – areas which are of utmost importance for the indi-
vidual patient in managing his/her everyday life with the
disease. These aspects are represented in the concept of
HRQoL. There is agreement that HRQoL describes “the
extent to which one’s usual or expected physical,
emotional, and social well-being is affected by a medical
condition or its treatment” ([6], p. 73) and needs to be
assessed as a patient-reported outcome (PRO). PROs
comprise any self-report of a patient’s health status with-
out interpretation by a third person [7].
The assessment of HRQoL as an important secondary
outcome in clinical studies, using reliable and valid self-
report instruments, has become the criterion standard in
oncology [8–10]. To date, systematic assessments of
HRQoL in patients with GEP-NET have hardly been
performed. High-quality information on HRQoL serves
a variety of purposes, from the development of targeted
interventions to informed decision making about treat-
ment options to the allocation of healthcare resources
[11].
Based on the assumptions above, we conducted a
systematic review on studies incorporating HRQoL in
patients with GEP-NET to evaluate the methodological
quality of HRQoL processing and reporting. In detail,
this review aims at investigating (i) the amount of
available information on HRQoL in patients with GEP-
NET, (ii) how HRQoL was assessed and reported, and
(iii) if the quality of HRQoL information provided
meets agreed standards.
Methods
We applied a systematic approach to identify and ap-
praise studies on HRQoL in GEP-NET patients. Criteria
for the selection, description and evaluation of studies
were based on the PRISMA (Preferred Reporting Items
of Systematic Reviews and Meta-Analyses) checklist
[12], the Cochrane Consumers and Communication
Review Group’s Extraction Template [13], and the Mini-
mum Standard Checklist for Evaluating HRQoL Out-
comes in Cancer Clinical Trials [14].
Search strategy
A systematic literature search was conducted in September
2014 and updated in July 2016 using PubMed, EMBASE,
and CENTRAL. We searched for original research articles
published in English, Italian, French, or German and
restricted the search to studies on humans. Combinations
of the following MeSH and free text terms were used: neu-
roendocrine tumors, digestive system neoplasms, neuroen-
docrine, endocrine, NET, foregut, midgut, hindgut, quality
of life, patient-reported, self-reported, well-being, psycho*.
An exemplary search history for PubMed is provided in
Appendix.
In addition, we also searched OpenGrey (http://www.
opengrey.eu) and BIOSIS previews (http://www.dimdi.de/
static/de/db/dbinfo/ba70.htm) for the identification of
grey literature. Database searches were augmented by a
manual search of reference lists of included articles to
identify further eligible studies not detected by our search
terms.
Inclusion criteria and data extraction
Due to the scarceness of studies on the topic of
HRQoL in patients with GEP-NET, it was decided not
to impose restriction criteria concerning study design
in order to comprehensively capture the available
information. Any study with a quantitative approach
assessing self-reported HRQoL was considered
eligible. Publications that were letters, editorials, nar-
rative reviews, and case reports were excluded. Meth-
odological studies on HRQoL in this patient group
(e.g., instrument development) were considered not
eligible. A data collection form was based on the
Cochrane Consumers and Communication Review
Group’s Extraction Template, adapted to study
requirements, pilot tested on five randomly selected
reports and refined accordingly.
Eligibility assessment and data extraction were per-
formed by two independent researchers. In the case of
disagreement, a third reviewer was consulted to reach
final consensus. For the assessment of interrater agree-
ment a simple Kappa calculation was performed, with
values between .61 and .80 indicating substantial and
of > .81 almost perfect agreement [15].
Study evaluation
For study evaluation we adapted the Minimum Standard
Checklist for Evaluating HRQoL Outcomes in Cancer
Clinical Trials [14] and the Consolidated Standards of
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Reporting Trials (CONSORT) PRO extension checklist
[16] for our requirements (i.e., applicable to a range of
different study designs in addition to randomised con-
trolled trials (RCTs)). Multiple reports on the same study
were linked together and were subsequently defined as
one study.
Quality criteria were defined according to study design
For all studies it was documented if:
 HRQoL was identified as primary or secondary
outcome in the abstract (for studies with more
than one outcome parameter),
 there was an a priori hypothesis concerning HRQoL
(not applicable if explorative),
 an explicit rationale for HRQoL instrument
selection was provided,
 the instrument was validated or psychometric
properties were reported or referenced,
 the HRQoL instrument was cancer-specific,
 the instrument administration was reported,
 missing data was documented or discussed,
 statistical considerations for dealing with missing
data were provided,
 reports on HRQoL results were complete and
scoring was correct,
 the issue of clinical significance had been addressed.
For cross-sectional studies it was additionally docu-
mented if:
 compliance was reported.
For all kinds of prospective studies it was addition-
ally documented if:
 baseline compliance was documented,
 the timing of assessment was reported.
For prospective and comparative studies it was
additionally documented if:
 statistical power or effect sizes for HRQoL results
were reported.
For studies with HRQoL as secondary outcome it
was additionally documented if:
 HRQoL results were considered in discussion
section.
Results
Study selection and study characteristics
The literature search yielded a total of 1506 records
(after removing duplicates). Figure 1 shows the flow-
Fig. 1 Flow-diagram of study selection process
Martini et al. Health and Quality of Life Outcomes  (2016) 14:127 Page 3 of 18
diagram of the selection process. We screened titles and
abstracts and excluded 88 case-reports and non-original
research reports such as comments and letters. Subse-
quently, 791 studies were excluded for not investigating
GEP-NET, and 566 were excluded for not investigating
HRQoL. Grey literature search yielded five conference
abstracts reporting on studies dealing with HRQoL
issues which were not (or not yet) published as full
reports and, therefore, not included in the review. Four
additional studies were identified by hand search of
reference lists of relevant articles. After these selection
steps, 65 potentially relevant full-text articles remained
and were assessed for eligibility. Out of these, 14 articles
were excluded from the review for the following reasons:
ten did not measure self-reported HRQoL (e.g., used the
Karnofsky Performance Score), and four were methodo-
logical studies either on HRQoL instrument develop-
ment or comparison of instruments. With a Kappa of
.818 (p ≤ .001) the level of agreement between the two
reviewers concerning inclusion or exclusion of a full-text
article assessed for eligibility was high.
In total, 51 articles, which reported on 48 separate
studies, were included. Eight were RCTs which assessed
HRQoL as a secondary outcome to the primary end-
points response, progression-free survival, or time to
progression. Additionally, 25 prospective studies, in-
cluding 15 phase II trials, and 15 observational cross-
sectional studies were identified.
Sample sizes ranged between 9 and 663 patients with a
median of 51. Most of the studies investigated patients
in an advanced stage of disease and administered the
European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire Core 30 (EORTC
QLQ-C30) for assessing HRQoL. In total, 22 studies
used either HRQoL or another PRO (e.g., fear of recur-
rence) as a primary outcome measure. Eight studies
compared HRQoL scores with normative values from
the national general population. For details on study
characteristics see Table 1.
Applied instruments for measuring health-related quality
of life
The majority of the reviewed studies (31/48) used the
EORTC QLQ-C30 [17], which is one of the most widely
used HRQoL questionnaire in oncology in Europe. It has
been shown to have good validity and reliability and
consists of 30 items incorporating five functional scales
(physical, role, emotional, cognitive, social), three symptom
scales (fatigue, nausea/vomiting, pain), six single items
(dyspnoea, insomnia, appetite loss, constipation, diarrhoea,
financial difficulties) and one scale assessing global health
status/QoL. Scores are linearly transformed to a 0–100
scale with higher scores representing a higher level of func-
tioning and a higher level of symptomatology, respectively.
As defined by Osoba et al. [18], mean changes in HRQoL
scores over time of 5 to 10 points are considered as “small”,
10 to 20 points as “moderate”, and more than 20 points as
“large” with regard to clinical relevance. The QLQ-C30 can
be supplemented with disease- and treatment-specific
modules. The NET-specific module, the QLQ-GI.NET21
[19], was used in four of the reviewed studies. It covers
issues specific for GEP-NET and is applicable to patients
suffering from endocrine or gastrointestinal symptoms.
One study used the QLQ-LMC21, which is a module for
patients with liver metastases from a colorectal tumour.
The same principle of adding disease- and treatment-
specific modules to a generic questionnaire is applied by
the Functional Assessment of Chronic Illness Therapy
(FACIT) measures, which is one of the most frequently
used HRQoL measurement systems in the US and
Canada. The core questionnaire, the Functional Assess-
ment of Cancer Therapy-General (FACT-G) [20], is
composed of 27 items assessing physical, emotional,
functional and social well-being. The FACT-G was used
in five studies; applied modules were the FACT-
Hepatobiliary, the FACT-Anemia, the FACIT-Diarrhea,
and the FACIT-Fatigue.
One study used the Patient-Reported Outcome Meas-
urement Information System 29-item Health Profile
(PROMIS-29) which measures HRQoL in seven domains
(depression, anxiety, physical function, pain interference,
fatigue, sleep disturbance, ability to participate in social
roles and activities) and was designed for patients with a
wide range of chronic diseases [21]. In another study the
Psychosocial Adjustment to Illness Scale (PAIS) was
used. The PAIS was designed as a semi-structured clin-
ical interview assessing a patient’s psychosocial adjust-
ment to medical illness in terms of multiple domains
(health care orientation, vocational environment, domes-
tic environment, sexual relationships, extended family
relationships, social environment, psychological distress)
[22].
Generic instruments, namely the 36-Item Short Form
Health Survey (SF-36), the 12-Item Short Form Health
Survey (SF-12), the Euroqol-5 Dimension (EQ-5D), the
General Health Questionnaire 30 (GHQ-30) and 12
(GHQ-12), and the French version of the Nottingham
Health Profile (ISPN), were used in 10 studies. These in-
struments assess physical, emotional, functional and so-
cial aspects that are applicable across patient groups and
diseases and are therefore less suitable for the identifica-
tion of cancer site- or problem-specific concerns [23].
Evaluation of methodological quality of HRQoL reporting
Detailed information for each study based on the
Minimum Standard Checklist for Evaluating HRQoL
Outcomes in Cancer Clinical Trials and the CON-
SORT PRO extension checklist is provided in Table 2.
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Table 1 Study characteristics of identified studies






Arnold et al., 2005 [52] N = 109, foregut, midgut NET, CUP (locally advanced,
metastatic)
octreotide octreotide + INT no QLQ-C30
Bajetta et al., 2006 [53] N = 60, well-differentiated intestinal, pancreatic,
bronchial NET, other, CUP (low-grade malignancy)
lan ATG lan MP no QLQ-C30
Caplin et al., 2014 [42] (CLARINET) N = 204, well- or moderately differentiated pancreatic,
midgut, hindgut NET, other, CUP (progressive,
metastatic)
lan ATG placebo no QLQ-C30, QLQ-GI.NET21
Jacobsen & Hanssen, 1995 [54] N = 11, intestinal NET, PNET (liver metastases) octreotide placebo
(cross-over design)
no GHQ-30, PAIS





capecitabine + streptozocin no QLQ-C30
Raymond et al., 2011 [56] N= 171, well-differentiated PNET (advanced, metastatic) sunitinib placebo no QLQ-C30
Rinke et al., 2009 [57] (PROMID) N = 85, well-differentiated midgut NET (metastatic) octreotide LAR placebo no QLQ-C30
Yao et al., 2016 [45] (RADIANT-4) N = 302, well-differentiated GI-NET, bronchopulmonary
NET (advanced, progressive)
everolimus placebo no FACT-G
Phase II studies
Bodei et al., 2011 [58] N= 51, bronchial, pancreatic, duodenal, ileal,
appendicular, sigma-rectal NET, CUP (progressive, other)
177Lu-DOTATATE - no QLQ-C30
Bushnell et al., 2010 [59] N = 90, carcinoid (metastatic, refractory to octreotide) 90Y-DOTADOC - no EQ-5D
Claringbold et al., 2011 [60] N = 33, well-differentiated NET (progressive) 177Lu-DOTATATE - no QLQ-C30
Cwikla et al., 2010 [61] N = 60, GEP-NET (progressive, metastatic) 90Y-DOTATATE - no QLQ-C30, QLQ-GI.NET21
Delpassand et al., 2014 [62] N = 37, GEP-NET (progressive) 177Lu-DOTATATE - no QLQ-C30
Ducreux et al., 2014 [43];
Mitry et al., 2014 [44] (BETTER)
N = 34, well-differentiated PNET (progressive, metastatic)












Khan et al., 2011 [64] N = 256, carcinoid, PNET, CUP, gastrinoma, glucagonoma,
insulinoma, VIPoma (with and without metastases)
177Lu-DOTATATE - yes QLQ-C30
Korse et al., 2009 [65] N = 39, GI-NET (advanced, metastatic) octreotide LAR - no QLQ-C30
Kulke et al., 2008 [66] N = 107, carcinoid, PNET (advanced) sunitinib - no EQ-5D, FACIT-Fatigue
scale
Kvols et al., 2012 [67] N = 45, GI-NET (advanced, metastatic) pasireotide - no FACIT-D
Martin-Richard et al., 2013 [68] N = 30, well-differentiated GEP-NET, bronchopulmonary
NET, CUP (progressive)


















Table 1 Study characteristics of identified studies (Continued)
Ruszniewski et al., 2004 [69] N = 71, foregut, midgut, hindgut NET, other
(not terminally ill)
lan PR - no QLQ-C30
Wymenga et al., 1999 [70] N = 55, carcinoid, gastrinoma, VIPoma (tumour stages
III and IV)
lan PR - no QLQ-C30
Zuetenhorst et al., 2004 [71] N = 26, well-differentiated ileo-cecal, gastric,
bronchopulmonary NET, CUP (metastatic)
INT followed by unlabelled
MIBG followed by 131I-MIBG
- no QLQ-C30
Prospective studies
Fröjd et al., 2007 [72];
Fröjd et al., 2009 [73]
N = 36, carcinoid (metastatic, other) INT; octreotide; INT +
octreotide; CTX; octreotide +
CTX; no treatment
normative data (subsample) yes QLQ-C30
Haugland et al., 2013 [74] N = 37, GI-NET (not terminally ill) medical treatment (n.s.) - yes SF-36
Kalinowski et al., 2009 [75] N = 9, bronchial, jejunal, ileal, gastric NET, PNET,
insulinoma (liver metastases)
90Y microspheres - no QLQ-C30, QLQ-LMC21
Kwekkeboom et al., 2003 [76] N = 35, GEP-NET (progressive, other) 177Lu-DOTATATE - no QLQ-C30
Larsson & Janson, 2008 [77] N = 18, midgut carcinoid (n.s.) INT - yes QLQ-C30, FACT-An
Larsson et al., 2001 [78] N = 24, midgut carcinoid (metastatic, other) INT; SSA; INT + SSA normative data yes QLQ-C30





Pasieka et al., 2004 [80] N = 24, small bowel carcinoid, medullary thyroid cancer,
CUP (progressive, metastatic)
131I-MIBG; 111In-octreotide - no ad hoc questionnaire






Teunissen et al., 2004 [82] N = 50, carcinoid, PNET, CUP, gastrinoma, insulinoma
(metastatic)
177Lu-DOTATATE - yes QLQ-C30
Cross-sectional studies
Beaumont et al., 2012 [83]; N = 663, carcinoid, islet cell, “do not know or not sure
which type” (local, regional, distant, currently not
present)
surgery; surgery + SSA;
other; no past/current
treatment
normative data yes SF-36, PROMIS global
health short form,
PROMIS-29Pearman et al., 2016 [84] -
Gelhorn et al., 2016 [85] N = 11, midgut, hindgut NET (metastatic) telotristat etiprate normative data yes QLQ-C30, QLQ-GI.NET21
Haugland et al., 2009 [86] N = 96, GI-NET (not terminally ill) INT; SSA; INT + SSA; CTX;
no treatment
normative data yes SF-36
Haugland et al., 2016 [87] N = 196, GI-NET (not terminally ill) medical treatment (n.s.) normative data yes SF-36
Larsson et al., 1998 [88] N= 17, carcinoid, PNET (not terminally ill) (+ staff,
N = 17)
INT; SSA; INT + SSA - yes QLQ-C30




Larsson, von Essen et al.,
1999 [90]


















Table 1 Study characteristics of identified studies (Continued)
Larsson et al., 2003 [91] N = 19, carcinoid (n.s.) (+ staff, N = 19) INT; SSA; INT + SSA - yes semi-structured
interviews
Larsson et al., 2007 [92] N = 83, carcinoid, PNET (n.s.) INT/octreotide; CTX; XTR;
omeprazol; no treatment
- yes QLQ-C30
Petzel et al., 2012 [93] N = 240, PNET, periampullary neoplasms (disease-free
after surgery)
no current treatment - yes FACT-Hep
Pezzilli et al., 2009 [94] N = 44 PNET (disease free, advanced) SSA; SSA + other; no
treatment
normative data yes SF-12, GHQ-12
Pezzilli et al., 2010 [95] N = 44 ileal NET (disease free, advanced) SSA; INT; CTX; SSA + other;
no treatment
yes SF-12
Ruszniewski et al., 2016 [96]
(SYMNET)
N = 273, small bowel carcinoid, appendicular, colonic,
bronchopulmonary NET, CUP (92 % with metastases)
lan ATG - yes QLQ-C30, QLQ-GI.NET
van der Horst-Schrivers et al.,
2009 [97]
N = 43, midgut NET (metastatic) SSA; INT; SSA + INT normative data yes QLQ-C30
von Essen et al., 2002 [98] N = 85, GI-NET (n.s.) INT; SSA; INT + SSA - yes QLQ-C30
Grey literature
Garcia-Hernandez et al., 2012 [99] N = 74, GI-NET (n.a.) n.a. - yes QLQ-C30, QLQ-GI.NET21
Gyökeres et al., 2010 [100] N = 93, GI-NET (59 % with metastases) SSA - yes QLQ-C30, QLQ-GI.NET21
Marinova et al., 2016 [101] N = 68, PNET (n.a.) PRRT (n.s.) - yes QLQ-C30
Pavel et al., 2013 [102] N = 126, PNET (advanced) everolimus - no QLQ-C30, QLQ-GI.NET21
Strosberg et al., 2015 [103] N = 230, midgut NET (advanced, progressive,
metastatic)
177Lu-DOTATATE octreotide LAR no QLQ-C30, QLQ-GI.NET21
Note. CUP cancer with unknown primary, CTX chemotherapy, GEP-NET gastroenteropancreatic NET, GI-NET gastrointestinal NET, INT interferon-α, lan ATG lanreotide autogel, lan MP lanreotide microparticles, lan PR lan-



















Table 2 Study evaluation according to defined quality criteria









































- - + + + - + + + - - - - +
Bajetta et al.,
2006 [53]








+ - - + -d - + + + - - - + +
Meyer et al.,
2014 [55]
+ - - + + - + + + - - - - -
Raymond et
al., 2011 [56]












- - - + + - - + - - - - - +
Bushnell et al.,
2010 [59]
- - - + - - + + + - - - - -
Claringbold et
al., 2011 [60]
- - - + + - - + + - - - - +
Cwikla et al.,
2010 [61]
- - - + + + - + + - - - - -
Delpassand et
al., 2014 [62]
- - - + + - - + + - - - - -
Ducreux et al.,
2014 [43];
























- - - + - - - + + - - - - -
Khan et al.,
2011 [64]
N/A - + + + + + + + - - - + +
Korse et al.,
2009 [65]
N/A - + + +d - - - + - - - - N/A
Kulke et al.,
2008 [66]
- - - + - + - + + - - - - +
Kvols et al.,
2012 [67]








- - - + + - + + + - - - - +
Wymenga et
al., 1999 [70]










N/A N/A - + +d + + + + + - + + N/A
Haugland et
al., 2013 [74]
N/A - - + - + + + + + + + - N/A
Kalinowski et
al., 2009 [75]








N/A N/A + + + - - + + - - + + N/A























- + - + -d + - + - - - + - +
Pasieka et al.,
2004 [80]
- - - - - + + + + - - - + +
Spolverato et
al., 2015 [81]
N/A + + - + + + + + - - - - N/A
Teunissen et
al., 2004 [82]










- N/A - + + + + N/A + - N/A - + +
Haugland et
al., 2009 [86]
N/A N/A + + - + + N/A + - + + + N/A
Haugland et
al., 2016 [87]
N/A + - + - + + N/A + + - - - N/A
Larsson et al.,
1998 [88]








N/A N/A + + +d + + N/A + - N/A + + N/A
Larsson et al.,
2003 [91]
N/A N/A N/A N/A N/A + - N/A + N/A N/A N/A N/A N/A
Larsson et al.,
2007 [92]
N/A N/A + + +d + + N/A + - N/A + - N/A
Petzel et al.,
2012 [93]
N/A + + + + + - N/A + + N/A + - N/A
Pezzilli et al.,
2009 [94]
N/A - - + - + + N/A + - - - - N/A
Pezzilli et al.,
2010 [95]
N/A - - + - + - N/A - - - - - N/A


























N/A N/A - + + + + N/A - - - + - N/A
von Essen et
al., 2002 [98]
N/A N/A - + + + + N/A + - - - - N/A
Note. ain the abstract of the article; bor psychometric properties reported; cconsidered adequate if scoring has been performed correctly and if all assessed HRQoL domains were reported (including relevant p-values);


















Figure 2 shows the percentage of studies meeting
the CONSORT PRO reporting criteria. The percent-
age of studies meeting additional quality criteria is
depicted in Fig. 3. It should be noted that stated
percentages do not always refer to all 48 extracted
studies, but to the total number of studies that met
the defined criteria.
Study evaluation revealed three major topics of con-
cern. The first is a lack of knowledge on how to assess
and process HRQoL data, and here particularly the
absence of a priori hypotheses on HRQoL outcomes in
85 % and missing rationales for applied questionnaires
in 70 % of studies. The second is a lack of adequate
reporting of HRQoL results. For 65 % of studies, the
presentation of results was rated inadequate, either
due to incomplete reporting of HRQoL scores (only
single scales or statistical significant results) or due to
invalid score calculation (i.e., not according to the
respective scoring manual). The third is related to the
statistical methods as well as interpretation and
discussion of HRQoL results. Information on the
handling of missing data was not given in 79 % of
studies. Less than one third of the studies (30 %)
addressed the issue of clinical significance of findings.
Further evaluation revealed that studies which investi-
gated HRQoL as a primary outcome showed higher
methodological quality of HRQoL data than those that
included HRQoL as a secondary outcome measure.
This was especially true for presentation and inter-
pretation of results.
Overview on HRQoL outcomes
From our literature search, we identified 8 RCTs
investigating a broad range of patient groups regarding
cancer site and stage, disease duration, as well as
treatment modality. According to the predefined
criteria, reporting of HRQoL data was of moderate to
poor quality, especially in terms of completeness and
adequate presentation of results. Thus, due to hetero-
geneity and methodological limitations of studies, no
firm conclusions for clinical practice can be drawn.
There is evidence from non-RCTs including HRQoL
as a primary outcome that patients with GEP-NET
perceive their overall HRQoL as relatively good and
stable. However, in-depth evaluation of these studies
revealed a range of physical and psychosocial complaints
primarily related to diarrhoea, flushing, and fatigue, as
well as emotional, social, and role functioning when
compared to the general population. Again, it has to be
noted that these results should be interpreted with
caution and not be considered as a basis for informing
clinical practice and decision making. A brief summary
of primary outcomes and HRQoL results of the reviewed
studies is provided in Additional file 1.
Discussion
The evaluation of HRQoL in patients with GEP-NET
has attracted increasing interest in recent years. Des-
pite this positive trend, however, there is still little
knowledge available on this topic, and existing studies
have major methodological limitations that hinder the
application of HRQoL findings in daily clinical prac-
tice. The aim of this review was to evaluate the meth-
odological quality of studies on HRQoL in GEP-NET
patients, from data collection through to interpret-
ation of results.
Our literature search yielded 58 abstracts ostensibly
dealing with HRQoL issues in GEP-NET patients. How-
ever, further evaluation reveals that ten of these studies
did not assess HRQoL at all but rather performed proxy
Fig. 2 Percentage of studies meeting CONSORT PRO extension criteria
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ratings on physical functioning and self-care abilities. As
the agreed definition of HRQoL is that it assesses a
range of health issues beyond physical abilities and inev-
itably comprises patients’ self-reports [7, 24–26], these
studies were excluded from the systematic review.
The evaluation of the remaining 48 studies, on a posi-
tive note, revealed a consistent application of appropri-
ate HRQoL instruments. The majority of studies (35/48)
used a cancer-specific questionnaire with already proven
reliability and validity. This finding is in line with previ-
ous studies on the quality of PRO reporting in oncology
RCTs, indicating that a majority of studies including
PROs used validated disease- or at least cancer-specific
instruments [27–29]. In the current review, nine studies
amended these questionnaires with ad hoc questions on
NET-specific symptoms, such as diarrhoea and hot
flushes. It should be noted, however, that this was done
in the absence of validated NET-specific PRO instru-
ments. One study, however, administered an ad hoc
instrument alone (i.e., not in combination with another
validated measure) and another study used a self-
constructed questionnaire comprising elements of vali-
dated measures. The term ‘ad hoc’ refers to the fact that
these questions were not formally developed and had
not undergone psychometric testing. In order to ensure
high methodological quality and improve comparability
of data across different studies, ad hoc questions should
be considered only, if there are no appropriate validated
PRO instruments [30, 31]. There is awareness of the fact
that novel treatment agents may entail a range of symp-
toms not currently covered by validated PRO/HRQoL
instruments [32–34] and methodological approaches of
addressing this issue are being discussed. The EORTC
Quality of Life Group (QLG) runs a database with an
item pool including all questions from the disease-
specific supplementary modules of the QLQ-C30, vali-
dated for cancer patients and different languages. Select-
ing suitable questions from such an item bank should be
preferred over designing ad hoc questions. For patients
with GEP-NET, two disease-specific questionnaires, the
EORTC QLQ-GI.NET21 [19], a module to be applied
together with the core questionnaire QLQ-C30, and the
Norfolk QOL-NET [35], a NET-specific stand-alone
measure, have become available only recently.
A range of methodological shortcomings were identified
in assessing and processing as well as in reporting and
interpreting HRQoL data. Most of the reviewed studies
were heterogeneous in terms of study design and quality
making it impossible to draw meaningful conclusions for
clinical practice at this point. This refers primarily to stud-
ies investigating HRQoL as a secondary outcome. A large
percentage of these studies provided only crude or incom-
plete presentations of HRQoL results or did not apply cor-
rect scoring procedures as prescribed by respective
manuals. One of the included RCTs used HRQoL as a sec-
ondary outcome, as indicated in the clinical trial protocol
as well as in the Methods section of the respective main
publication, but failed to report on these issues both in the
Results and Discussion section. Another common limita-
tion was the lack of information on the statistical
approach of handling missing HRQoL data, which was
also found in previous reviews including different malig-
nancies such as brain, bladder, prostate, and gynaeco-
logical cancers [27, 28, 36, 37]. These limitations were
apparent even in high-evidence studies that are likely to
impact on health policy and practice. None of the eight
RCTs included in this review could provide HRQoL infor-
mation in a way that would allow its use for informed
decision making and planning future trials. Thus, while
acknowledging the need for assessing HRQoL as an
important secondary outcome in clinical studies, there
seems to be an uncertainty about the processing of the
collected data [14, 38–40]. Similar to the results of previ-
ous studies investigating the methodological quality of
PRO reporting in patients with brain [27], prostate [36],
and gynaecological [28] cancers, further problems were
related to the interpretation of HRQoL results, especially
regarding the clinical significance of HRQoL findings (e.g.,
changes over time, differences between treatment arms).
Studies included in this review that used HRQoL as a pri-
mary outcome provided evidence that patients present
with impairments in multiple domains such as emotional,
role, and social functioning when compared to general
population norms. This is in contrast to findings showing
that GEP-NET patients generally perceived their HRQoL
as relatively good. As mentioned above, to date, existing
Fig. 3 Percentage of studies meeting additional quality criteria from
HRQoL checklist
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studies do not allow for firm conclusions and call for fur-
ther research to elucidate the time course of HRQoL in
this patient group.
Two recent review articles [29, 39] evaluating the meth-
odological quality of PRO reporting in high-evidence stud-
ies on different cancer types indicated that the overall level
of reporting according to the CONSORT PRO extension
criteria was poor. Exceptions were studies assessing HRQoL
as a primary outcome and/or presenting a supplementary
report on HRQoL issues which showed a better perform-
ance. The overall quality of PRO reporting might benefit
from increasing familiarity with HRQoL issues and the de-
velopment of the above mentioned guidelines [29, 36, 39].
However, in spite of this development, a recent review on
the consistency of available PRO-specific guidance has
identified a clear lack of respective recommendations for
the appropriate implementation of PROs in clinical
research [41]. Although the checklists applied in this review
[14, 16] do not represent an exhaustive set of criteria for
high-quality HRQoL assessment for studies including
HRQoL either as a primary or secondary outcome, their ap-
plication both during study planning and reporting would
substantially enhance the quality of the assessed data.
Therefore, while agreeing that further guidance is
required to make HRQoL assessment more feasible
and – with increasing quality – accessible for clinical
use, we emphasise the need to adhere to already
existing quality standards. Important scientific soci-
eties that have shaped the field of HRQoL research in
oncology over the past two decades, such as the
EORTC QLG, the FACIT group and the International
Society for Quality of Life Research (ISOQOL), pro-
vide a well-informed basis for the application of PROs
and should therefore be consulted when considering
their incorporation into clinical trials.
In the field of GEP-NET research, there is a growing
number of clinical trials considering HRQoL as an
outcome measure [42–48]. However, two recent, not yet
published, phase III trials fail to incorporate PRO or
HRQoL assessments, as indicated in the respective study
protocols [49, 50]. Furthermore, the methodological qual-
ity of information derived thus far is not satisfactory. Con-
sidering the fact that such studies have the potential to
impact on health policy and practice, the importance of
generating high-quality HRQoL data cannot be overstated.
Poorly designed and/or reported PROs are likely to
undermine the credibility of the results, which in
turn hinders their application in daily clinical prac-
tice [9, 14, 27, 29, 37, 39, 40]. Especially with the
movement towards a more patient-centred health
care system, the incorporation of the patient’s sub-
jective perspective plays a pivotal role in facilitating
patient involvement in health care, thereby enhancing
patient empowerment and satisfaction [51].
Conclusions
Despite an increasing interest in assessing HRQoL in pa-
tients with GEP-NET, there is still little knowledge on
the course of HRQoL over time, highlighting the need
for high-quality longitudinal studies. Existing studies
show methodological shortcomings in both processing
and reporting of HRQoL data, especially when included
as a secondary outcome in clinical trials. Methodological
limitations were identified even for studies with high evi-
dence level, which is considered problematic given their
impact on health policy and medical practice. Thus, the
valid application of HRQoL findings in clinical practice
is hampered not only by lack of studies, but also by vari-
ous methodological limitations of the existing ones.
High-quality, well-reported HRQoL data is of utmost
importance to make results accessible and useful to pa-
tients and their treating physicians. Therefore, it is
strongly recommended to adhere to existing guidelines
on the incorporation of PROs into clinical research.
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